Diagnostic Rentability of Screening for Associated Conditions in Calcium Pyrophosphate Deposition Disease Patients

This study has been completed.
Sponsor:
Information provided by:
Sociedade Galega de Reumatoloxía
ClinicalTrials.gov Identifier:
NCT00453128
First received: March 26, 2007
Last updated: March 27, 2007
Last verified: March 2007
  Purpose

The purpose of this study is to determine whether thorough analytical evaluation is useful to diagnose metabolic conditions associated to calcium pyrophosphate deposition disease.


Condition
Chondrocalcinosis

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Longitudinal
Official Title: Appraisal of the Diagnostic Rentability of Thorough Analytical Screening Searching Associated Conditions in Patients Newly Diagnosed With Calcium Pyrophosphate Dihydrate Deposition Disease

Resource links provided by NLM:


Further study details as provided by Sociedade Galega de Reumatoloxía:

Estimated Enrollment: 240
Study Start Date: January 1997
Study Completion Date: December 2006
Detailed Description:

The diagnostic usefulness of screening for hyperparathyroidism, hemochromatosis, hypothyroidism and hypophosphatasia in patients diagnosed with calcium pyrophosphate dihydrate (CPPD) deposition disease is uncertain.

Patients diagnosed with CPPD deposition disease were compared to patients with rheumatoid arthritis and psoriatic arthritis over a 9-year period. All patients were prospectively followed for at least 12 months. Serum calcium, phosphorus, alkaline phosphatase, thyroid-stimulating hormone, ferritin, iron, and total iron binding capacity were determined in all patients.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients diagnosed as having calcium pyrophosphate dihydrate deposition disease.

Exclusion Criteria:

  • Patients mimicking a rheumatoid arthritis disease, with positive rheumatoid factor or with psoriasis.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00453128

Locations
Spain
Meixoeiro Hospital
Vigo, Pontevedra, Spain, 36214
Sponsors and Collaborators
Sociedade Galega de Reumatoloxía
Investigators
Principal Investigator: José M Pego-Reigosa, MD, PhD Meixoeiro Hospital, Vigo (Pontevedra) SPAIN
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00453128     History of Changes
Other Study ID Numbers: SGR1
Study First Received: March 26, 2007
Last Updated: March 27, 2007
Health Authority: Spain: Ministry of Health

Keywords provided by Sociedade Galega de Reumatoloxía:
Calcium Pyrophosphate
associated conditions

Additional relevant MeSH terms:
Chondrocalcinosis
Arthritis
Joint Diseases
Musculoskeletal Diseases

ClinicalTrials.gov processed this record on July 31, 2014